YKL-40 predicts poor prognosis for bladder cancer
As reported in Urologic Oncology, the gene expression and serum level of YKL-40 are higher in patients with bladder cancer than healthy controls. Serum YKL-40 levels predict poor prognosis in patients with muscle-invasive bladder cancer (HR=1.75).
Increased incidence of second primary cancers in patients with salivary gland tumors
As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.
Cisplatin monotherapy effective in pediatric high-risk hepatoblastoma
As reported in the Journal of Pediatric Hematology/Oncology, treatment of children with high-risk hepatoblastoma (n=14) with cisplatin monotherapy was as effective as cisplatin + doxorubicin combination therapy, but with less toxicity. The complete resection rate was 78.6%, the event-free survival rate was 81.8%, and the OS rate was 100%.